泽姆沃克斯 ZYME
$29.63 +$0.90 (+3.11%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $29.63 0.00%
开盘$28.74
昨收$28.74
当日区间$28.40 – $29.92
成交量908.0K
市值$2.09B
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例98.7%+0.31 个百分点，较上季度
持仓机构数254-3 ，较上季度
内部人近期交易31次买入 / 4次卖出净买入
空头持仓比例7.77% 占流通股回补天数 4.4 · 截至 15 Oct 2026
卖空成交量占比21.1%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：−$11.24M（3个净流入日，17个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有59.3%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从5.58%升至7.77%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +256,042 | 2.1% |
| Macquarie Investment Management Business Trust | Mutual Fund | 2026/Q3 | +868,354 | 1.3% |
| Perceptive Advisors LLC | VC/PE Fund | 2026/Q3 | +672,875 | 5.9% |
| Delaware Management Company | Mutual Fund | 2026/Q3 | +600,846 | 0.8% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +524,041 | 1.8% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +340,363 | 0.5% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +298,931 | 0.4% |
| Prosight Management, LP | Hedge Fund | 2026/Q3 | +135,385 | 1.0% |
| Scotia Wealth Management | Bank/Investment Bank | 2026/Q3 | +118,100 | 0.2% |
| Nomura Investments Fund Advisers | Mutual Fund | 2026/Q3 | +99,256 | 0.1% |
| State of Wisconsin Investment Board | Government Pension Fund | 2026/Q3 | +89,473 | 0.2% |
| Granahan Investment Management, LLC | Mutual Fund | 2026/Q3 | +85,384 | 0.5% |
| Y-Intercept (Hong Kong) Limited | Mutual Fund | 2026/Q3 | +83,455 | 0.1% |
| LMR Partners LLP | Hedge Fund | 2026/Q3 | +82,500 | 0.1% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +81,653 | 0.8% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 8 Oct 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Derivative Exercise and Sale | -13,832 | $25.85 | 23,205 |
| 8 Oct 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Derivative Exercise and Retained | +23,205 | – | 23,205 |
| 5 Jul 2026 | Mark Hollywood | Chief Operating Officer | Other Acquisition | +939 | $22.22 | 133,852 |
| 12 May 2026 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +119,000 | – | 119,000 |
| 12 May 2026 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +178,000 | $24.57 | 178,000 |
| 12 May 2026 | Paul Schneider | Executive Vice President | Initial Statement of Beneficial | +0 | – | – |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +47,000 | – | 47,000 |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +70,000 | $27.35 | 70,000 |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +76,000 | – | 76,000 |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Initial Statement of Beneficial | +0 | – | 167,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +47,000 | – | 47,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +70,000 | $27.35 | 70,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +76,000 | – | 76,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Initial Statement of Beneficial | +0 | – | 167,000 |
| 5 Apr 2026 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +169,000 | – | 50,000 |
| 5 Apr 2026 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +178,000 | $25.84 | 178,000 |
| 31 Mar 2026 | Kristin Stafford | Chief Financial Officer | Initial Statement of Beneficial | +0 | – | – |
| 31 Jan 2026 | Sabeen Mekan | Senior VP & Chief Medical Officer | Initial Statement of Beneficial | +0 | – | 221,000 |
| 11 Jan 2026 | Kenneth Galbraith | Chairperson & CEO | Derivative Exercise and Sale | -30,424 | $22.67 | 226,842 |
| 11 Jan 2026 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +144,000 | – | 144,000 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 5,577,540 | 7.8% | 4.4 |
| 30 Sep 2026 | 5,291,136 | 7.4% | 5.6 |
| 15 Sep 2026 | 4,939,072 | 7.0% | 8.0 |
| 31 Aug 2026 | 4,724,831 | 6.7% | 5.7 |
| 14 Aug 2026 | 4,538,353 | 6.4% | 8.5 |
| 31 Jul 2026 | 4,106,590 | 5.6% | 10.9 |
暂无评论——快来第一个聊聊 ZYME。
登录后参与讨论。